S

Sanofi

Global pharma company; vaccines and R&D

Global Project Head - Vaccines R&D

Full-TimePosted on 10/15/2026Deadline 10/23/26
$232.5k - $335.8k
Senior
Master's, PharmD, PhD, MD
Swiftwater, PA, USA+1 moreMore locations: Waltham, MA, USA
Hybrid
Biology & Biotech

About the job

Requirements
  • A Master of Science degree in a scientific-related field of study is required.
  • At least 7 years of experience in drug development is required; experience in vaccines or infectious disease is preferred.
  • Ability to lead international, cross-functional teams toward common goals.
  • Ability to build trust and foster collaboration across diverse teams and cultures.
  • Ability to inspire and motivate others to achieve excellence.
  • Ability to navigate ambiguity and drive clarity in complex situations.
  • Presentation skills to distill complex information into compelling narratives.
  • Negotiation skills and ability to build consensus among stakeholders with different perspectives.
  • Commercial awareness and understanding of market dynamics.
  • Adaptability and resilience in the face of challenges and changing priorities.
  • Intellectual curiosity and commitment to continuous learning.
  • Passion for improving patient lives and advancing global health.
Responsibilities
  • Contribute to the creation and implementation of high-level product development strategies, including the Target Product/Vaccine Profile (TPP/TVP).
  • Develop and execute project strategy from Gate M2 through licensure and lifecycle management, aligning it with organizational objectives and patient needs.
  • Drive strategic decisions balancing scientific innovation, commercial viability, and patient impact.
  • Ensure project deliverables meet timelines, quality standards, and regulatory requirements across all markets.
  • Structure and lead the Global Project Team, fostering a collaborative, high-performance culture.
  • Set clear objectives, provide constructive feedback, and hold team members accountable for deliverables.
  • Mentor and develop team members, building capabilities across the organization.
  • Create an inclusive environment where diverse perspectives are valued and leveraged.
  • Supervise project activities and resolve resource-utilization issues across functions.
  • Optimize allocation of budget, personnel, and materials to maximize project efficiency.
  • Partner with functional leaders to secure necessary resources and capabilities, and make data-driven decisions regarding resource prioritization and trade-offs.
  • Translate the Target Product Profile into comprehensive scope, objectives, and actionable plans.
  • Ensure alignment across the Integrated Early Global Plan, Integrated Strategic Commercial Plan, Clinical Development Plan, Technical Strategy Document, and Global Regulatory Plan and Strategy.
  • Anticipate future needs and proactively adapt strategies to changing landscapes.
  • Drive innovation in development approaches and methodologies.
  • Manage relationships with internal and external stakeholders at the executive level.
  • Build consensus among diverse stakeholder groups with competing priorities.
  • Navigate complex organizational dynamics to advance project objectives.
  • Represent the project in high-level strategic discussions and governance forums.
  • Champion project objectives, progress, and risk-mitigation strategies across all organizational levels.
  • Present to senior leadership, governance committees, and external partners.
  • Ensure transparent, timely communication of project status, challenges, and opportunities.
  • Tailor messaging to scientific experts and business leaders.
  • Manage strategic relationships with NGOs, partner companies, academic groups, and joint ventures.
  • Negotiate and oversee collaboration agreements that advance project goals.
  • Ensure alignment between internal objectives and external partner expectations.
  • Leverage external partnerships to access capabilities, expertise, and resources.
  • Contribute to development of a unified R&D vision and strategic roadmap for the franchise.
  • Integrate project strategy with broader portfolio and franchise objectives.
  • Identify opportunities for synergies across projects and therapeutic areas.
  • Participate in long-term strategic planning and portfolio optimization.
Desired Qualifications
  • A PhD, MD, or PharmD degree is preferred.
  • Experience in vaccines or infectious disease is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

INACTIVE